Why the study?
Does the addition of a primary prophylactic dose of low molecular weight heparin (LMWH) to standard treatment improve 1-year survival in patients with newly diagnosed lung cancer?
Does the addition of a primary prophylactic dose of low molecular weight heparin (LMWH) to standard treatment improve 1-year survival in patients with newly diagnosed lung cancer?
The addition of prophylactic LMWH to standard therapy in newly diagnosed lung cancer patients does not improve overall survival, though it significantly reduces VTE risk at the cost of increased clinically relevant nonmajor bleeding.
No takes yet. Share an insight, caveat, or question.
Prophylactic LMWH does not improve survival in newly diagnosed lung cancer; confirms neutral effect on overall survival despite VTE reduction.
Macbeth et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: